search
Back to results

Comparison of NoaScope to the Conventional Stethoscope for Auscultation of Heart and Lung Sounds

Primary Purpose

Chest Pathology

Status
Completed
Phase
Not Applicable
Locations
Pakistan
Study Type
Interventional
Intervention
NoaScope
Sponsored by
Innova Smart Technologies (Pvt.) Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Chest Pathology

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Ages: 18 years or older (male and female)
  • Hospital admitted or Out Patient Department
  • Written consent provided

Exclusion Criteria:

  • Age <18
  • ICU admitted
  • Written consent not provided

Sites / Locations

  • Rehman Medical Institute - RMI

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Auscultation with a newly developed electronic stethoscope: NoaScope

Arm Description

Identification of abnormal heart and lung sounds in study participants

Outcomes

Primary Outcome Measures

Correctly identified abnormal heart and lung sounds by doctors using two stethoscopes: NoaScope and 3M™️ Littmann®️ Classic III.
Each patient will receive two auscultation examinations: one with NoaScope and another with 3M™️ Littmann®️ Classic III. The investigators will determine the clinical feasibility and non-inferiority of NoaScope to the FDA-approved 3M™️ Littmann®️ Classic III from auscultation findings (heart and lungs) by doctors (holding varied levels of clinical expertise). Doctors will examine each patient using two stethoscopes: NoaScope and 3M™️ Littmann®️ Classic III. The investigators will also measure inter and intra observer agreement by the Kappa index with the help of a questionnaire. Kappa values < 0.8 means weak to moderate level of agreement and Kappa values between 0.8 - 1.0 would mean strong level of agreement.
The measurement of sound quality in a clinical setting by means of an MOS scale on a questionnaire.
The investigators will measure sound quality on a mean opinion score scale with values ranging form 1 (bad) to 5 (excellent).

Secondary Outcome Measures

Difference in performance between subgroups of doctors based on clinical experience.
This will be estimated as a proportion difference of correctly identified heart and lung sounds for each doctor subgroup.

Full Information

First Posted
December 24, 2021
Last Updated
April 4, 2023
Sponsor
Innova Smart Technologies (Pvt.) Ltd
Collaborators
Rehman Medical Institute - RMI, NOABIO LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT05252130
Brief Title
Comparison of NoaScope to the Conventional Stethoscope for Auscultation of Heart and Lung Sounds
Official Title
Comparison of NoaScope to the Conventional Stethoscope for Auscultation of Heart and Lung Sounds
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Completed
Study Start Date
December 22, 2021 (Actual)
Primary Completion Date
January 31, 2022 (Actual)
Study Completion Date
February 10, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Innova Smart Technologies (Pvt.) Ltd
Collaborators
Rehman Medical Institute - RMI, NOABIO LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes

5. Study Description

Brief Summary
Assessing non-inferiority of a newly developed electronic stethoscope NoaScope in comparison with the conventional 3M Littmann stethoscope
Detailed Description
The enrolled population will include adults with a history of heart and lung complications. The enhanced sound quality of the electronic stethoscope and its non-inferiority to the traditional/conventional 3M Littmann stethoscope will be assessed through auscultation examination of every patient by a health professional (consultant, medical resident, and house officer) with both the electronic stethoscope and 3M Littmann/traditional/conventional stethoscope

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chest Pathology

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
47 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Auscultation with a newly developed electronic stethoscope: NoaScope
Arm Type
Experimental
Arm Description
Identification of abnormal heart and lung sounds in study participants
Intervention Type
Device
Intervention Name(s)
NoaScope
Intervention Description
Smart digital stethoscope
Primary Outcome Measure Information:
Title
Correctly identified abnormal heart and lung sounds by doctors using two stethoscopes: NoaScope and 3M™️ Littmann®️ Classic III.
Description
Each patient will receive two auscultation examinations: one with NoaScope and another with 3M™️ Littmann®️ Classic III. The investigators will determine the clinical feasibility and non-inferiority of NoaScope to the FDA-approved 3M™️ Littmann®️ Classic III from auscultation findings (heart and lungs) by doctors (holding varied levels of clinical expertise). Doctors will examine each patient using two stethoscopes: NoaScope and 3M™️ Littmann®️ Classic III. The investigators will also measure inter and intra observer agreement by the Kappa index with the help of a questionnaire. Kappa values < 0.8 means weak to moderate level of agreement and Kappa values between 0.8 - 1.0 would mean strong level of agreement.
Time Frame
1 month
Title
The measurement of sound quality in a clinical setting by means of an MOS scale on a questionnaire.
Description
The investigators will measure sound quality on a mean opinion score scale with values ranging form 1 (bad) to 5 (excellent).
Time Frame
1 month
Secondary Outcome Measure Information:
Title
Difference in performance between subgroups of doctors based on clinical experience.
Description
This will be estimated as a proportion difference of correctly identified heart and lung sounds for each doctor subgroup.
Time Frame
1 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Ages: 18 years or older (male and female) Hospital admitted or Out Patient Department Written consent provided Exclusion Criteria: Age <18 ICU admitted Written consent not provided
Facility Information:
Facility Name
Rehman Medical Institute - RMI
City
Peshawar
State/Province
KP
ZIP/Postal Code
25000
Country
Pakistan

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Comparison of NoaScope to the Conventional Stethoscope for Auscultation of Heart and Lung Sounds

We'll reach out to this number within 24 hrs